Navigation Links
Litigation Predicted in Wake of FAA Ban of Chantix Use by Pilots and Air Traffic Controllers: Smoking Cessation Drug Target of Controversy
Date:5/22/2008

BIRMINGHAM, Ala., May 22 /PRNewswire/ -- A veteran pharmaceutical litigation attorney predicted today that pharmaceutical giant Pfizer will face lawsuits from individuals who claim to have been harmed by its popular smoking cessation drug Chantix. The FAA issued an immediate ban on the use of Chantix by pilots and air traffic controllers on May 21 after receiving an analysis of adverse events published by the Institute for Safe Medication. The report cites cases that allege Chantix may cause serious unintended side effects including loss of consciousness.

Kristian Rasmussen, a veteran pharmaceutical litigation attorney with the law firm Cory Watson Crowder & DeGaris said, "The magnitude of the health risks associated with Chantix is alarming - we are trying to determine whether the drug maker, Pfizer, failed to disclose information it may have had about adverse side effects." Rasmussen said his team, that includes pharmaceutical and medical experts along with attorneys, has been investigating reports of devastating side effects for more than year. "What we are finding is that the magnitude of the safety signal associated with using Chantix is alarming both in terms of severity of injury and the number of different serious reactions," said Rasmussen.

After requesting an accelerated review by the FDA, Chantix was approved for use in the U.S. in May, 2006. Chantix revenues hit $883 million in 2007, according to corporate performance reports available on the company's website. The Institute for Safe Medication report, cited in the FAA's ban on Chantix use among pilots and air traffic controllers, is the latest in a serious of reports highlighting concerns about the drug. In November, 2007, the U.S. Food and Drug Administration released a Preliminary Assessment specifically highlighting the number of reports noting an association between suicide and attempted suicide within days to weeks of initiating Chantix treatment.

On February 1, 2008, public health concerns intensified when the FDA issued a Public Health Advisory stating that "Serious neuropsychiatric symptoms have occurred in patients taking Chantix." Symptoms outlined include changes in behavior, agitation, depressed mood, suicidal ideation, and attempted and completed suicide. Rasmussen says more studies are likely as attorneys move forward with litigation.

About Cory Watson Crowder & DeGaris

Cory Watson Crowder & DeGaris is recognized nationally for its practice in mass torts litigation, multidistrict litigation and complex litigation including class actions, products liability, business and securities litigation, environmental litigation and mass torts litigation of defective medical devices and pharmaceuticals.


'/>"/>
SOURCE Cory Watson Crowder & DeGaris
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Warner Chilcott Announces Settlement of Securities Litigation
2. Seattle-Based Law Firm Williams Kastner Receives Significant Defense Verdict in Trade Secret Business Litigation Case
3. KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation
4. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
5. Peter Burg Appointed as Co-Chair of the Plaintiffs Steering Committee and the Executive Committee for the Gadolinium-Based Contrast Agents Product Liability Multi-District Litigation
6. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
7. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
8. Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
9. Information About The Airborne Health, Inc. Settlement, and Other Ongoing Litigation Alleging False and Deceptive Marketing Of Airborne(R)
10. Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation
11. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology: